Medico-economic Evaluation of Therapeutic Adaptation Guided by the Soluble Suppression of Tumorigenicity 2 (sST-2) Biomarker in the Management of Patients With Acute Heart Failure
Status: Recruiting
Location: See all (12) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Management of patients with heart Failure remains a major health concern because of the high rate of rehospitalization, mortality and induced-cost. Biomarkers could help to guide the management of patients with heart failure (HF). Soluble suppression of tumorigenicity 2 (sST2) appears as a promising biomarker. As a working hypothesis, we postulate that sST2 values monitoring could be an helpful guide for medical management in an attempt to reduce hospital readmission.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• 18 years or older
• Hospitalization for heart failure (NTproBNP(N-terminal pro-Brain Natriuretic Peptid) ≥450 pg/ml (ou BNP ≥400 pg/ml)
Locations
Other Locations
France
CHU Angers
RECRUITING
Angers
CHU Besançon
RECRUITING
Besançon
CH Béziers
RECRUITING
Béziers
CHU Caen
RECRUITING
Caen
CHU Grenoble
RECRUITING
Grenoble
Arnaud de Villeneuve Hospital
RECRUITING
Montpellier
Lapeyronie Hospital
ACTIVE_NOT_RECRUITING
Montpellier
CHU Nimes
RECRUITING
Nîmes
APHP Pompidou
NOT_YET_RECRUITING
Paris
CHU Rennes
NOT_YET_RECRUITING
Rennes
CHU Toulouse
RECRUITING
Toulouse
CHU Vannes
RECRUITING
Vannes
Contact Information
Primary
Jean-Paul CRISTOL, MD, PhD
jp-cristol@chu-montpellier.fr
(0)4 67 33 83 14
Backup
Anne-Marie GORCE DUPUY
am-dupuy@chu-montpellier.fr
(0)4 67 33 79 61
Time Frame
Start Date: 2021-04-27
Estimated Completion Date: 2027-01
Participants
Target number of participants: 710
Treatments
No_intervention: Control
Usual management of heart failure. The sST-2 level will be blunted.
Experimental: Biomarker guided therapy
Guided therapy using sST-2 monitoring at the discharge from initial hospitalisation, 6, 12, 18 and 24 months of following.
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Montpellier
Collaborators: EURO BIO Scientific